Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.96 +1.27 (+7.18%)
Streaming Delayed Price Updated: 11:40 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views ↗
 
Via Benzinga
Topics Earnings
News headline image
Top movers analysis in the middle of the day on 2025-07-29: top gainers and losers in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Sarepta Stock Soars After FDA Says It Can Resume Drug Shipments ↗
Sarepta stock soared after the FDA said the biotech company can resume shipments of a controversial gene therapy drug. 
Via Investor's Business Daily
Topics Workforce
News headline image
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
This Sarepta Therapeutics Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? ↗
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,... 
Via Benzinga
News headline image
Nvidia, Sarepta, HPE, Citi, EQT: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗
Sarepta stock’s after-hours jump came as the FDA notified the company that it could lift the voluntary pause on the shipments. 
Via Stocktwits
Topics Artificial Intelligence Credit Cards
News headline image
BitMine Immersion, Sarepta Therapeutics, CEA Industries, Super Micro Computer And AMD: Why These 5 Stocks Are On Investors' Radars Today ↗
U.S. markets closed mixed on Monday, with the Dow Jones Industrial Average slipping 0.1% to 44,837.56. 
Via Benzinga
Topics Stocks
News headline image
Why Sarepta Therapeutics Stock Surged Nearly 48% In After-Hours Trading Today ↗
The FDA concluded that a recent patient death in Brazil was unrelated to Sarepta’s Elevidys treatment, allowing the company to resume U.S. shipments for boys who can still walk. 
Via Stocktwits
News headline image
HIMS and SRPT ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients ↗
Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys. 
Via Benzinga
News headline image
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. 
Via Benzinga
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy ↗
The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation from European regulators to reject approval of Elevidys. 
Via Stocktwits
Topics Death
News headline image
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗
Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward. 
Via Stocktwits
Topics Death
News headline image
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe ↗
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys. 
Via Investor's Business Daily
Topics Death
News headline image
Sarepta Therapeutics, Inc. Class Action: Levi &amp; Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.